Taiwan - Delayed Quote TWD

Kim Forest Enterprise Co., Ltd. (6645.TW)

Compare
16.85
-1.70
(-9.16%)
At close: 1:24:00 PM GMT+8
Loading Chart for 6645.TW
  • Previous Close 18.55
  • Open 18.30
  • Bid --
  • Ask --
  • Day's Range 16.70 - 18.30
  • 52 Week Range 16.70 - 40.00
  • Volume 114,410
  • Avg. Volume 38,771
  • Market Cap (intraday) 1.129B
  • Beta (5Y Monthly) -0.11
  • PE Ratio (TTM) --
  • EPS (TTM) -2.74
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date Jun 20, 2023
  • 1y Target Est --

Kim Forest Enterprise Co., Ltd. provides precision medical products. It offers devices, reagents, and analysis pipelines to health care providers, which include screening tests for cancer and inherited diseases. The company also provides genetic testing, drug report, and monitoring tools for cancer patients; and a non-invasive genome-wide health assessment for healthy persons. In addition, it offers bioinformatics service items; prenatal test kits; and genetically modified models. Further, the company offers SARS-CoV-2 detection kits. The company was founded in 2004 and is headquartered in New Taipei City, Taiwan.

www.kimforest.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 6645.TW

View More

Performance Overview: 6645.TW

Trailing total returns as of 4/9/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

6645.TW
29.50%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
24.50%

1-Year Return

6645.TW
55.10%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
16.37%

3-Year Return

6645.TW
28.56%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
0.62%

5-Year Return

6645.TW
4.94%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
71.87%

Compare To: 6645.TW

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 6645.TW

View More

Valuation Measures

Annual
As of 4/9/2025
  • Market Cap

    1.03B

  • Enterprise Value

    1.17B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.78

  • Price/Book (mrq)

    1.61

  • Enterprise Value/Revenue

    2.34

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -31.88%

  • Return on Assets (ttm)

    -9.77%

  • Return on Equity (ttm)

    -26.34%

  • Revenue (ttm)

    501.53M

  • Net Income Avi to Common (ttm)

    -159.88M

  • Diluted EPS (ttm)

    -2.74

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    217.86M

  • Total Debt/Equity (mrq)

    57.28%

  • Levered Free Cash Flow (ttm)

    -239.01M

Research Analysis: 6645.TW

View More

Company Insights: 6645.TW

Research Reports: 6645.TW

View More